Maxim Group reissued their buy rating on shares of Palisade Bio (NASDAQ:PALI – Free Report) in a report released on Wednesday, Benzinga reports. Maxim Group currently has a $22.50 price objective on the stock. Palisade Bio Price Performance NASDAQ:PALI opened at $7.08 on Wednesday. The company’s 50 day moving average is $5.70 and its 200-day […]
Maxim Group restated their buy rating on shares of Palisade Bio (NASDAQ:PALI – Free Report) in a research report report published on Tuesday, Benzinga reports. The firm currently has a $22.50 price target on the stock. Palisade Bio Price Performance Shares of Palisade Bio stock opened at $4.71 on Tuesday. Palisade Bio has a 1 […]
Palisade Bio, Inc. (NASDAQ:PALI – Get Free Report) was the target of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 2,000,000 shares, an increase of 1,450.4% from the January 15th total of 129,000 shares. Currently, 25.7% of the company’s stock are short sold. […]
Bruce Sands, MD, MS., Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai and System Chief, Division of Gastroenterology,.